BioMarin Pharmaceuticals BMRN Restricted cash equivalents included in Other long-term assets

Other financials

Revenue$766.2M+2.8%

Gross profit$571.2M-3.8%

Operating income$129.6M-42.1%

Net income$105.5M-43.2%

EPS (diluted)$0.54-43.2%

Cash & equivalents$3.1B+193%

Total debt$1.4B+138%

Total equity$6.2B+7.2%

Total assets$8.6B+20.2%

Operating cash flow$220.7M+26.5%

CapEx$20.9M+24.8%

Free cash flow$199.7M+26.7%

Market cap$10.57B-19.4%

Enterprise value$8.93B-29.3%

P/E21.1×-22.7×

P/S3.3×-1.2×

Gross margin76.5%-2.9pp

Operating margin19.9%+7.2pp

Net margin16.8%+5.1pp

FCF margin23.7%+2.5pp

Return on equity9.1%+2.8pp

Debt / equity0.2×+0.1×

Current ratio5.8×+0.3×

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashEquivalentsNoncurrent.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is BioMarin Pharmaceuticals's restricted cash equivalents included in other long-term assets?: BioMarin Pharmaceuticals (BMRN) reported restricted cash equivalents included in other long-term assets of $850M in Q1 2026.